Skip navigation
Watchlist Sponsored By :

As of Friday, November 6th:
The blended earnings growth rate for the S&P 500 for Q3 2009, combining actual numbers for companies that have reported, and estimates for companies yet to report rose to -14.8% from -15.5% in the previous day.
As of October 1st, the earnings growth rate was at -24.8%.Of the 440 S&P 500 companies who have reported Q3, 80% beat estimates, 6% were in-line, and 14% were below estimates.  The blended earnings growth rate for the S&P 500 for Q3 2009 is currently at -14.8%. (Data provided by Thomson Reuters)

LATEST EARNINGS RESULTS


Current DateTime: 06:08:30 12 Nov 2009
LinksList Documentid: 29017166
Expiration DateTime: 11/12/2009 6:09:26 AM

Current DateTime: 06:08:31 12 Nov 2009
LinksList Documentid: 24355697

FEATURED QUIZZES


Current DateTime: 06:08:31 12 Nov 2009
LinksList Documentid: 33793611
  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

  • The Many Myths of Coca-Cola

      Can you tell which statements are true, and which ones are just rumors?

  • Think You Understand Markets?

      We've selected some questions from the Financial Industry Regulatory Authority's test of investor knowledge. See how you do ...


Current DateTime: 06:08:31 12 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
Wyeth Profit Falls, Hurt by Charges
By: Reuters | 18 Oct 2007 | 07:36 AM ET
Text Size

Wyeth said Thursday that third-quarter earnings fell slightly, hurt by charges tied to productivity initiatives that offset higher sales of its pharmaceutical products.

Wyeth [WYE  Loading...      ()   ], which has endured a string of setbacks to its experimental drugs, also launched a $5 billion stock buyback program.

Profit fell to $1.15 billion, or 84 cents per share, from $1.16 billion, or 85 cents per share, a year earlier.

Excluding a charge tied to productivity initiatives, earnings were 90 cents per share, matching the analysts' average forecast compiled by Reuters Estimates. Revenue rose 9 percent to $5.62 billion.

Sales of Wyeth's Prevnar vaccine to prevent childhood infections rose 24 percent to $634 million. Sales of its Effexor antidepressant rose 4 percent to $958 million.

Copyright 2009 Reuters. Click for restrictions.
Tools:
Print EmailAdd This share icon

Current DateTime: 06:08:31 12 Nov 2009
LinksList Documentid: 29016957
Expiration DateTime: 11/12/2009 6:09:57 AM

Current DateTime: 06:08:31 12 Nov 2009
LinksList Documentid: 29017287
Expiration DateTime: 11/12/2009 6:09:27 AM


Current DateTime: 05:31:44 12 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:07:47 12 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 01:07:47 12 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:01:49 12 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters